Efficacy of interrupted cyclic treatment with prednisolone on cancer pain: a randomized crossover study

Abstract Background Interrupted cyclic treatment with a low oral dose of prednisolone combined with stepladder analgesics would reduce the pain scores in cancer patients with reported less side effects. Following ethical approval, 39 cancer patients were randomized to receive prednisolone 10 mg ever...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Mohamed A. Ghanem
Formato:	article
Lenguaje:	EN
Publicado:	SpringerOpen 2021
Materias:	Interrupted cyclic Prednisolone Cancer pain Pain Cancer Genomic Anesthesiology RD78.3-87.3 Medical emergencies. Critical care. Intensive care. First aid RC86-88.9
Acceso en línea:	https://doaj.org/article/c3d4cb40abed4751b84b7efa390baae4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c3d4cb40abed4751b84b7efa390baae4
record_format	dspace
spelling	oai:doaj.org-article:c3d4cb40abed4751b84b7efa390baae42021-11-21T12:04:52ZEfficacy of interrupted cyclic treatment with prednisolone on cancer pain: a randomized crossover study10.1186/s42077-021-00169-z2090-925Xhttps://doaj.org/article/c3d4cb40abed4751b84b7efa390baae42021-11-01T00:00:00Zhttps://doi.org/10.1186/s42077-021-00169-zhttps://doaj.org/toc/2090-925XAbstract Background Interrupted cyclic treatment with a low oral dose of prednisolone combined with stepladder analgesics would reduce the pain scores in cancer patients with reported less side effects. Following ethical approval, 39 cancer patients were randomized to receive prednisolone 10 mg every other day or every 4th day for 4 successive weeks followed with tapering prednisolone by 2.5 mg every 4 days over 2 weeks after each interval, primary outcome visual analog score (VAS), and other secondary outcomes such as (A) patient demographics; (B) pain scores; brief pain inventory score (BPI), pain severity score (PSS), pain interference score (PIS), analgesia level score, pain level score (PLS), and pain management index (PMI)); and (C) patient safety (adverse effects) with interrupted cyclic treatment with low-dose prednisolone. Results Compared with baseline values, patients had statistically significant lower VAS and PSS pain scores at 14 and 28 days after starting the 2 days cyclic treatment with prednisolone. Patients had comparative VAS and PSS pain scores during the 4-day cyclic treatment with prednisolone. Compared with the 4-day cyclic treatment, patients in the 2-day cyclic treatment had significant statistically lower VAS pain scores at 28 days. Adverse effects showed no significant statistical differences during both study sequences. Conclusion Interrupted cyclic prednisolone 10 mg combined with stepladder analgesic regimen is effective and safe in terms on improved quality of analgesia for 28 days in cancer patients more when used every 2nd day than every 4th day with appetite improvement during both. Trial registration The study protocol was approved by the local Institutional Board Review Committee on 8-11-2019. The study was prospectively registered with the www.clinicaltrials.govMohamed A. GhanemSpringerOpenarticleInterrupted cyclicPrednisoloneCancer painPainCancerGenomicAnesthesiologyRD78.3-87.3Medical emergencies. Critical care. Intensive care. First aidRC86-88.9ENAin Shams Journal of Anesthesiology, Vol 13, Iss 1, Pp 1-9 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Interrupted cyclic Prednisolone Cancer pain Pain Cancer Genomic Anesthesiology RD78.3-87.3 Medical emergencies. Critical care. Intensive care. First aid RC86-88.9
spellingShingle	Interrupted cyclic Prednisolone Cancer pain Pain Cancer Genomic Anesthesiology RD78.3-87.3 Medical emergencies. Critical care. Intensive care. First aid RC86-88.9 Mohamed A. Ghanem Efficacy of interrupted cyclic treatment with prednisolone on cancer pain: a randomized crossover study
description	Abstract Background Interrupted cyclic treatment with a low oral dose of prednisolone combined with stepladder analgesics would reduce the pain scores in cancer patients with reported less side effects. Following ethical approval, 39 cancer patients were randomized to receive prednisolone 10 mg every other day or every 4th day for 4 successive weeks followed with tapering prednisolone by 2.5 mg every 4 days over 2 weeks after each interval, primary outcome visual analog score (VAS), and other secondary outcomes such as (A) patient demographics; (B) pain scores; brief pain inventory score (BPI), pain severity score (PSS), pain interference score (PIS), analgesia level score, pain level score (PLS), and pain management index (PMI)); and (C) patient safety (adverse effects) with interrupted cyclic treatment with low-dose prednisolone. Results Compared with baseline values, patients had statistically significant lower VAS and PSS pain scores at 14 and 28 days after starting the 2 days cyclic treatment with prednisolone. Patients had comparative VAS and PSS pain scores during the 4-day cyclic treatment with prednisolone. Compared with the 4-day cyclic treatment, patients in the 2-day cyclic treatment had significant statistically lower VAS pain scores at 28 days. Adverse effects showed no significant statistical differences during both study sequences. Conclusion Interrupted cyclic prednisolone 10 mg combined with stepladder analgesic regimen is effective and safe in terms on improved quality of analgesia for 28 days in cancer patients more when used every 2nd day than every 4th day with appetite improvement during both. Trial registration The study protocol was approved by the local Institutional Board Review Committee on 8-11-2019. The study was prospectively registered with the www.clinicaltrials.gov
format	article
author	Mohamed A. Ghanem
author_facet	Mohamed A. Ghanem
author_sort	Mohamed A. Ghanem
title	Efficacy of interrupted cyclic treatment with prednisolone on cancer pain: a randomized crossover study
title_short	Efficacy of interrupted cyclic treatment with prednisolone on cancer pain: a randomized crossover study
title_full	Efficacy of interrupted cyclic treatment with prednisolone on cancer pain: a randomized crossover study
title_fullStr	Efficacy of interrupted cyclic treatment with prednisolone on cancer pain: a randomized crossover study
title_full_unstemmed	Efficacy of interrupted cyclic treatment with prednisolone on cancer pain: a randomized crossover study
title_sort	efficacy of interrupted cyclic treatment with prednisolone on cancer pain: a randomized crossover study
publisher	SpringerOpen
publishDate	2021
url	https://doaj.org/article/c3d4cb40abed4751b84b7efa390baae4
work_keys_str_mv	AT mohamedaghanem efficacyofinterruptedcyclictreatmentwithprednisoloneoncancerpainarandomizedcrossoverstudy
_version_	1718419269583110144

Efficacy of interrupted cyclic treatment with prednisolone on cancer pain: a randomized crossover study

Ejemplares similares